Month: September 2020

TORONTO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Loncor Resources Inc. (“Loncor” or the “Company“) (TSX: “LN”; OTCQX: “LONCF”; FSE: “LO51”) is pleased to announce that the recent exploration results have outlined a number of significant, undrilled mineralised trends at its 84.68%-owned Imbo Project. The focus of exploration by Loncor during 2020 has been along trend in the southeast of the Imbo Project from the 2.5 million ounce Adumbi, Kitenge and Manzako deposits (inferred mineral resources of 30.65 million tonnes grading 2.54 g/t Au) previously delineated in the northwest of the 122 square kilometre project area.Commenting on these results, Loncor’s President Peter Cowley said: “Situated approximately 9 kilometres from our key deposit of Adumbi, we are very encouraged by the exploration...

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 entitled “Anhydrous Sodium Thiosulfate and Formulations Thereof.”  As suggested by the title, the patent captures the unique anhydrous form of the active ingredient in Fennec’s PEDMARK product, as well as related methods of synthesis.  This patent is eligible for listing in the U.S Food and Drug Administration (FDA) Orange Book, and reflects Fennec’s strategy to expand and diversify its intellectual property portfolio to obtain...

NASDAQ   OMX Copenhagen A/S

JACKSONVILLE, FL, Sept. 21, 2020 (GLOBE NEWSWIRE) — BOTS, Inc. (OTC: BTZI) (GERMAN EXCHANGE: M06.SG), an emerging innovator of products, technologies, and services for the rapidly growing digital robotic automation and manufacturing industry announced today that the Company is offering a portfolio of Cyber Security Services including cyber threat monitoring and analysis through Israel based operations centers, real-time monitoring, and industry-specific threat intelligence and incident response services. The Company is developing plans to set up operations centers in the U.S. BOTS Inc cybersecurity services are supported by a cloud-based platform that delivers an uninterrupted threat intelligence monitoring through a portal that will be available on the Company website.“Cybersecurity has become one of the most critical business...

Samsett hlutfall* í ágúst 2020 var 93,1% og það sem af er ári er 108,9%. Samsett hlutfall síðustu 12 mánaða er 104,6%. Við sjáum áfram merki um lækkun á tíðni tjóna sem endurspeglast í samsettu hlutfalli í ágúst. Ávöxtun fjárfestingaeigna í ágúst var 1,1% en ávöxtun til loka ágúst frá áramótum var 6,0%. *Samsett hlutfall er tjónakostnaður, endurtryggingakostnaður og rekstrarkostnaður af vátryggingastarfsemi sem hlutfall af iðgjöldum tímabilsins samkvæmt leiðbeinandi tilmælum Seðlabanka Íslands, fjármálaeftirlits nr. 1/2020. 

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 23, 2020 at 9:10am ET.The 40-minute live presentation will include a company overview and update by Mr. Yeh, with analyses of data on TLC’s pain programs – TLC599 and TLC590 – by Dr. Spencer-Green. During the virtual conference, which takes place September 21-23, 2020, TLC will also be participating in one-on-one sessions.The corporate presentation is available on the TLC website at www.tlcbio.com...

Reference is made to the stock exchange notice of Aqua Bio Technology ASA (the “Company“) dated 18 August 2020 regarding completion of two private placements and to a stock exchange notice dated 11 September 2020 regarding completion of a subsequent offering.Through these share capital increases the share capital of the Company has been increased with NOK 7,578,000 through issuance of 3,031,200 new shares, each with a par value of NOK 2.50.The share capital increases pertaining to the above share issues has now been registered in the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 45,998,427.50 divided by 18,399,371 shares, each with a par value of NOK 2.50. The new shares will be admitted to trading on Oslo Axess as soon as possible under ticker “ABT”.For further information,...

Det vises til børsmelding fra Aqua Bio Technology ASA (“Selskapet“) datert 18. august 2020 vedrørende gjennomføring av to rettede emisjoner og til børsmelding datert 11. september 2020 vedrørende gjennomføring av en etterfølgende emisjon.Gjennom disse tre kapitalforhøyelser er Selskapets aksjekapital økt med NOK 7 578 000 gjennom utstedelse av 3 031 200 nye aksjer, hver pålydende NOK 2,50.Kapitalforhøyelsene knyttet til ovennevnte emisjoner er nå registrert i Foretaksregisteret. Den nye aksjekapitalen i Selskapet er NOK 45 998 427,50 fordelt på 18 399 371 aksjer, hver pålydende NOK 2,50. De nye aksjene vil noteres på Oslo Axess så snart som mulig under ticker “ABT”.For nærmere informasjon, kontakt Espen Kvale, konst. adm.dir, telefon +47 916 28 092 eller per e-post espen.kvale@aquabiotech.no.Aqua Bio Technology...

Orphazyme A/SCompany announcement                                                                                       No. 51/2020                                                                                                          Company Registration No. 32266355Copenhagen, Denmark, September 21, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the -Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the Extraordinary General Meeting:Approved an amendment to an authorization to the Board of Directors to increase the share capital of the Company without pre-emption rights for existing shareholdersApproved an authorization to the Board of Directors to decide whether a general meeting shall be held fully by electronic meansApproved...

COPENHAGEN, Denmark, Sept. 21, 2020 (GLOBE NEWSWIRE) — Compass Lexecon, a subsidiary of FTI Consulting, Inc. (NYSE: FCN), today announced the opening of an office in Copenhagen, Denmark, and the appointment of Thomas Rønde, Professor of Innovation and Entrepreneurship at Copenhagen Business School and former Chief Economist at the Danish Competition and Consumer Authority, as an Academic Affiliate.Professor Rønde is a recognized economics expert in competition policy and regulation and has extensive experience in advising firms and agencies in Denmark and abroad on cases and policy. His recent consultancy experience includes advising on the merger between the energy companies SE and Eniig in 2019 and the proposed merger between house-building companies HusCompagniet and eurodan. He previously worked at the University of Mannheim...